European Union

EPO Patent Application: Controlled Poration Methods

The European Patent Office has published patent application EP2026030613A1 concerning systems, devices, and methods for controlled poration and substance delivery into the cellular nucleus. The application was published on March 18, 2026, and lists various IPC classifications related to biotechnology and cell manipulation.

EPO Patent Application EP2026030628A2: Proteomics and ML Discovery Methods

The European Patent Office has published patent application EP2026030628A2 concerning methods for target, biomarker, and patient selection discovery using cell-type specific spatial proteomics and machine learning. The application details novel approaches for drug discovery and development.

EPO Patent: Synthesis of 1-Butanol from Carbon Dioxide by Engineered Bacteria

The European Patent Office has published a patent application (EP2026030726A1) detailing the synthesis of 1-butanol from carbon dioxide using engineered bacteria. The patent application was published on March 18, 2026, and lists designated states across Europe.

EPO Patent Publication: Rock Hyrax IPSC Generation Methods

The European Patent Office has published a patent application (EP2026030659A1) detailing methods for generating induced pluripotent stem cells (IPSC) from rock hyrax. The publication date is March 18, 2026, and it includes IPC classifications related to cell culture and genetic manipulation.

EPO Patent Publication: Enterotoxigenic E. coli Fusion Antigen

The European Patent Office has published a patent application (EP2026030712A1) related to enterotoxigenic E. coli fusion antigen proteins and their use. The publication date is March 18, 2026, and the inventors have not yet been designated.

EPO Patent Publication: Blood Brain Barrier Penetrant AAV Capsids

The European Patent Office (EPO) has published a patent application (EP2026030714A1) concerning pharmaceutical compositions containing blood-brain barrier penetrant AAV capsids. The publication date is March 18, 2026, and it covers various designated states within the European Union.

EPO Patent Application: Protein Design Systems and Methods

The European Patent Office has published patent application EP2026030717A1 concerning protein design systems and methods. The application was published on March 18, 2026, and includes classifications related to biotechnology and artificial intelligence. The inventors have not yet been designated.

EPO Patent EP2026030729A1: RXR Agonist for Treating Cancer

The European Patent Office has published patent application EP2026030729A1 concerning the use of an RXR agonist for treating cancer. The publication date is March 18, 2026, and it includes IPC classifications related to pharmaceutical compositions and therapeutic uses.

EPO Patent Grant EP2699693B1 for Isolating Target Analyte

The European Patent Office has granted patent EP2699693B1 for methods of isolating a target analyte from a heterogeneous sample. The patent lists multiple inventors and covers various International Patent Classifications related to molecular biology and analytical chemistry.

EPO Patent Publication: Polynucleotide Influenza Vaccine

The European Patent Office has published a patent application (EP2026030759A1) for a polynucleotide influenza vaccine encoding hemagglutinin and neuraminidase. The publication date is March 18, 2026, and it includes IPC classifications related to vaccines and molecular biology.